Traditional Chinese medicine composition, preparation method thereof and application of traditional Chinese medicine composition in preparation of medicine for preventing and treating thyroid diseases

By using traditional Chinese medicine compositions of cat claw grass, dandelion, xiangfu and tiankuizi, the problems of complex and unknown toxic side effects of traditional Chinese medicine prescriptions are solved, effective treatment of thyroid nodules is achieved, and thyroid function and inflammatory factors are reduced. It significantly reduces the thyroid nodules and is safe.

CN119074841AActive Publication Date: 2024-12-06GUANGDONG PHARMA UNIV +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410883368.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-03
Publication Date
2024-12-06
Estimated Expiration
2044-07-03

AI Technical Summary

Technical Problem

The existing traditional Chinese medicine prescriptions for treating thyroid nodules have complex components, unknown toxicity and long treatment time, and traditional surgery and radioiodine treatment are at risk of recurrence and hypofunction.

Method used

Using a traditional Chinese medicine composition composed of cat claw grass, dandelion, scented amoe and tiankui seeds, it is prepared by mixing and crushing or extraction to provide a safer and more effective method for treating thyroid nodules.

Benefits of technology

It significantly reduces the level of thyroid function and the expression of inflammatory factors in the serum, significantly reduces the size of thyroid nodules, improves thyroid function, relieves symptoms, and is safe and does not affect liver and kidney function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074841A_ABST
    Figure CN119074841A_ABST
Patent Text Reader

Abstract

The invention relates to a traditional Chinese medicine composition and a preparation method and application thereof in preparation of drugs for preventing and treating thyroid diseases, and belongs to the technical field of traditional Chinese medicine, the traditional Chinese medicine composition is prepared from radix ranunculi ternati, dandelion, rhizoma cyperi and radix semiaquilegiae, and the preparation method comprises the following steps: mixing and crushing the radix ranunculi ternati, the dandelion, the rhizoma cyperi and the radix semiaquilegiae according to the formula ratio; or extracting the radix ranunculi ternati, the dandelion, the rhizoma cyperi and the radix semiaquilegiae according to the formula amount. By compounding the radix ranunculi ternati, the dandelion, the rhizoma cyperi and the radix semiaquilegiae, hypothyroidism, thyroid nodules and the like caused by thyroid hormone deficiency can be remarkably treated, and compared with the prior art, the traditional Chinese medicine composition is definite in component, good in safety and better in treatment effect, and provides technical support for treating thyroid diseases through traditional Chinese medicine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition and a preparation method thereof, and application of the traditional Chinese medicine composition in preparing medicines for preventing and treating thyroid diseases. Background Art

[0002] Thyroid nodules are a common disease of the endocrine system, including nodular goiter, thyroid adenoma, acute thyroiditis, hyperthyroidism, and thyroid papillary microcarcinoma. Thyroid nodules are a global public health problem. With the accelerated pace of modern life, the probability of people suffering from thyroid nodules is increasing year by year.

[0003] The most common treatments for thyroid nodules include radioactive iodine therapy, antithyroid drug therapy, hormone replacement therapy, and surgery, which are still controversial. Patients with Graves' disease who are younger, have larger thyroid nodules, or have a larger thyroid volume have a higher risk of recurrence after stopping antithyroid drug therapy. Surgery can treat thyroid nodules, however, total thyroidectomy will lead to permanent hypothyroidism, requiring lifelong supplementation of thyroid-stimulating hormone, while subtotal thyroidectomy will lead to recurrence. When radioactive iodine treatment is performed on thyroid nodules, THs levels should be monitored regularly because hypothyroidism will occur within 2-3 years after treatment. Therefore, it is necessary to find a safer and more effective way to treat thyroid nodules.

[0004] CN109568477A discloses a pharmaceutical composition for treating thyroid nodules, which is a preparation prepared from the following raw materials in weight ratio: 9-15 parts of Cyperus rotundus, 9-15 parts of White Peony Root, 16-24 parts of Sargassum, 8-12 parts of Bupleurum, 12-18 parts of Kelp, 30-45 parts of Fritillaria, 8-12 parts of Pinellia, 5-7 parts of Pericarpium Citri Reticulatae, 8-12 parts of Tangerine Peel, 12-18 parts of Angelica Sinensis, 8-12 parts of Chuanxiong, 8-12 parts of Forsythiae, 12-18 parts of Raw Oyster, and 7-11 parts of Prunella Vulgaris. The invention can significantly alleviate the clinical symptoms of patients with thyroid nodules and effectively treat thyroid nodules.

[0005] CN113209208A discloses a Chinese medicine composition for treating thyroid nodules and a preparation method thereof, wherein the raw materials for preparing the Chinese medicine composition include bupleurum, fructus aurantii, cyperus rotundus, cat's claw, dragon bone, oyster, ligusticum chuanxiong, red peony root, dried orange peel, pinellia tuber, and liquorice. The invention can effectively improve the clinical symptoms of patients with thyroid nodules, regulate the level of thyroid hormones, control and delay the development of thyroid nodules, improve the size of nodules, regulate the overall function of patients, change the physical problems prone to thyroid nodules, and intervene fundamentally.

[0006] CN110393781A discloses a pure Chinese medicine preparation for treating thyroid nodules, which comprises the following ingredients by weight volume ratio: 15-30 parts of Prunella Vulgaris, 15-30 parts of Taraxacum officinale, 10-20 parts of Forsythia suspensa, 10-20 parts of Fritillaria thunbergii, 30-60 parts of raw oyster, 10-20 parts of Cat's Claw, 15-20 parts of Gleditsia sinensis, 10-20 parts of Curcuma aromatica, 20-30 parts of raw turtle shell, 5-10 parts of Tripterygium wilfordii and 10-15 parts of Glechoma longituba. The invention can significantly reduce the size of thyroid nodules, eliminate the clinical symptoms of patients and relieve pain.

[0007] Compared with Western medicine, TCM has obvious advantages in treating thyroid nodules. It is safe and can largely avoid the risks of drug dependence and thyroid function changes caused by long-term oral hormone drugs, lifelong thyroid hormone drug dependence and nodule recurrence caused by surgical resection of thyroid nodules. However, the current TCM formulas for treating thyroid diseases still have problems such as complex ingredients, unknown toxic and side effects, and long treatment time. Summary of the invention

[0008] In view of the above technical problems, the present invention provides a Chinese medicine composition and a preparation method thereof and application of the composition in preparing drugs for preventing and treating thyroid diseases.

[0009] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0010] In a first aspect, the present invention provides a traditional Chinese medicine composition consisting of cat's claw, dandelion, cyperus rotundus and amaranth seed.

[0011] In the present invention, Ranunculus ternatus Thunb. is a perennial herbaceous plant of the genus Ranunculaceae, and its tuberous root can be used as medicine, and is sweet and spicy, warm in nature, and has the effects of dispersing nodules and reducing swelling. It is used for scrofula that has not yet ulcerated and lymphatic tuberculosis. Taraxacum is a commonly used Chinese medicine, and the whole plant is used as medicine, containing ingredients such as taraxasterol, taraxacetol, taraxein, caffeic acid, choline, inulin, etc., which can clear away heat and detoxify, reduce swelling and dissipate nodules; Radix Glechomae can also clear away heat and detoxify, reduce swelling and dissipate nodules, and is mainly used to treat scrofula; Rhizoma Cyperi can be antibacterial and analgesic, and has the effects of promoting qi and relieving depression. The present invention utilizes the compounding of four Chinese medicines, has clear ingredients, good safety, and can significantly treat thyroid nodules caused by insufficient thyroid hormone.

[0012] In some preferred embodiments, the Chinese medicine composition is composed of the following raw materials in parts by weight: 1-120 parts of cat's claw, 1-30 parts of dandelion, 1-20 parts of cyperus rotundus and 1-20 parts of amaranth seeds.

[0013] In some preferred embodiments, the Chinese medicine composition is composed of the following raw materials in parts by weight: 1-100 parts of cat's claw, 1-25 parts of dandelion, 1-18 parts of cyperus rotundus and 1-18 parts of aster seeds.

[0014] In some preferred embodiments, the Chinese medicine composition is composed of the following raw materials in parts by weight: 1-80 parts of cat's claw, 1-20 parts of dandelion, 1-15 parts of cyperus rotundus and 1-15 parts of amaranth seeds.

[0015] In some preferred embodiments, the Chinese medicine composition is composed of the following raw materials in parts by weight: 1-50 parts of cat's claw, 1-18 parts of dandelion, 1-12 parts of cyperus rotundus and 1-12 parts of aster seeds.

[0016] In some preferred embodiments, the Chinese medicine composition is composed of the following raw materials in parts by weight: 1-20 parts of cat's claw, 1-15 parts of dandelion, 1-10 parts of cyperus rotundus and 1-10 parts of aster seeds.

[0017] In some preferred embodiments, the Chinese medicine composition is composed of the following raw materials in parts by weight: 1-15 parts of cat's claw, 1-10 parts of dandelion, 1-8 parts of cyperus rotundus and 1-8 parts of amaranth seeds.

[0018] In some preferred embodiments, the mass ratio of cat's claw, dandelion, cyperus rotundus and angelica dahurica is 5-6:1-4:2-8:2-6; further preferably, it is 5-6:3-4:2-3:2-3, and most preferably, it is 5:3:2:2.

[0019] In a second aspect, the present invention provides a method for preparing the above-mentioned Chinese medicine composition, comprising the following steps: mixing and crushing the formulated amounts of cat's claw, dandelion, cyperus rotundus and galangal seeds; or

[0020] Extracting the formulated amounts of cat's claw, dandelion, cyperus rotundus and thyme seeds, purifying and enriching them, thus obtaining the traditional Chinese medicine composition.

[0021] The extraction in the present invention can be performed by extracting each herb separately and then mixing it for use, or by mixing each herb and then extracting it together.

[0022] In some embodiments, the method further includes crushing before extraction, wherein the formulated amount of cat's claw, dandelion, cyperus rotundus and geranium seeds are crushed before extraction.

[0023] In some embodiments, the extraction is water extraction and / or alcohol extraction.

[0024] In some embodiments, the extraction is water extraction, comprising the steps of:

[0025] The Chinese medicine composition is obtained by mixing the formulated amounts of cat's claw, dandelion, cyperus rotundus and galangal seeds, extracting with water, and combining the filtrates.

[0026] Preferably, the amount of water used is 5-20 times, preferably 8-12 times, and more preferably 10-11 times the total amount of the extracted raw materials.

[0027] Preferably, the water extraction is performed at least once, preferably 1-3 times, and more preferably 2-3 times; the time for each extraction is 0.5-3 hours, preferably 1-2.5 hours, and more preferably 1-2 hours.

[0028] In some embodiments, the combining of the filtrates further comprises concentration and / or drying.

[0029] In a third aspect, the present invention provides the use of the aforementioned Chinese medicine composition in the preparation of a drug for increasing thyroid hormone to treat diseases.

[0030] In some embodiments, the disease comprises hypothyroidism and / or thyroid nodules.

[0031] In some embodiments, the thyroid nodule comprises at least one of nodular goiter, thyroid adenoma, acute thyroiditis, chronic thyroiditis and thyroid micropapillary carcinoma.

[0032] In a fourth aspect, the present invention provides use of the aforementioned Chinese medicine composition in the preparation of a drug for treating diseases by reducing THs levels.

[0033] In some embodiments, the THs include at least one of T4, T3, and TSH.

[0034] In some embodiments, the disease comprises hypothyroidism and / or thyroid nodules.

[0035] In some embodiments, the thyroid nodule comprises at least one of nodular goiter, thyroid adenoma, acute thyroiditis, chronic thyroiditis and thyroid micropapillary carcinoma.

[0036] In a fifth aspect, the present invention provides use of the aforementioned Chinese medicine composition in the preparation of a medicament for treating hypothyroidism.

[0037] In a sixth aspect, the present invention provides use of the aforementioned Chinese medicine composition in the preparation of a medicament for treating thyroid nodules.

[0038] In some embodiments, the thyroid nodule comprises at least one of nodular goiter, thyroid adenoma, acute thyroiditis, chronic thyroiditis and thyroid micropapillary carcinoma.

[0039] The Chinese medicine composition of the present invention can achieve auxiliary treatment of thyroid diseases by reducing the thyroid function level and / or the expression of inflammatory factors in serum.

[0040] In some embodiments, the thyroid function level includes at least one of tetraiodothyronine level, triiodothyronine level, and thyroid stimulating hormone level.

[0041] In some embodiments, the inflammatory factors include IL-6 and / or TNF-α.

[0042] In a seventh aspect, the present invention provides a pharmaceutical composition for treating thyroid diseases, comprising the aforementioned Chinese medicine composition and pharmaceutically acceptable excipients.

[0043] In some embodiments, the dosage form of the pharmaceutical composition is tablets, pills, pellets, capsules, granules, powders, suppositories, powders, ointments, patches, injections, oral solutions, suspensions, sprays, lotions, drops, liniments or emulsions; preferably tablets, capsules, granules, powders or solutions.

[0044] Compared with the prior art, the present invention has the following beneficial effects:

[0045] (1) The present invention utilizes a compound of four Chinese medicinal herbs, namely, cat's claw, dandelion, cyperus rotundus and aster seeds, to significantly treat thyroid nodules caused by thyroid hormone deficiency. Compared with the prior art, the present invention has clear ingredients, good safety and better treatment effect.

[0046] (2) The present invention studies the mechanism of Chinese medicine components in treating thyroid nodules, and provides technical support for the treatment of thyroid diseases with Chinese medicine. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] Figure 1 SD rat thyroid nodule model;

[0048] Figure 2 SD rat thyroid tissue;

[0049] Figure 3 This is the changing trend of AST, ALT and BUN levels in the serum of SD rats. DETAILED DESCRIPTION

[0050] The present invention is described below through specific embodiments to make the technical solution of the present invention easier to understand and grasp, but the present invention is not limited thereto, and the described embodiments are only a part of the embodiments of the present invention, rather than all of the embodiments.

[0051] The endpoints and any value of the scope disclosed in this article are not limited to the accurate scope or value, and these scopes or values ​​should be understood to include values ​​close to these scopes or values. For numerical ranges, between the endpoint values ​​of each scope, between the endpoint values ​​of each scope and a separate point value, and between separate point values, one or more new numerical ranges can be combined with each other, and these numerical ranges should be considered as specifically disclosed in this article. Unless the context clearly indicates otherwise, the singular form "one", "a kind of" and "described" as used herein include singular and plural indicators. The numerical range described by the endpoint is included in all numerical values ​​and fractions within the corresponding range, as well as the described endpoint.

[0052] the term

[0053] In this article, THs is the thyroid function level, T4 is tetraiodothyronine, T3 is triiodothyronine, TSH is thyroid-stimulating hormone, IL-6 is interleukin 6, and TNF-α is tumor necrosis factor.

[0054] The "medicine" described in the present invention includes the aforementioned Chinese medicine composition or pharmaceutical composition and acceptable excipients. In a specific embodiment, the Chinese medicine composition or pharmaceutical composition described in the present invention is provided in the medicine in an effective amount (e.g., a therapeutically effective amount).

[0055] The "pharmaceutically acceptable excipients" described in the present invention include inert diluents, dispersants and / or granulating agents, surfactants and / or emulsifiers, disintegrants, binders, preservatives, buffers, lubricants and / or oils. Excipients (such as cocoa butter and suppository wax), colorants, coating agents, sweeteners, flavoring agents and aromatics may also be present in the pharmaceutical composition.

[0056] The "drug" described in the present invention can be prepared by any method known in pharmacy. Generally speaking, these preparation methods include associating the aforementioned Chinese medicine composition (i.e., the first active ingredient) with a carrier or excipient and / or one or more other auxiliary ingredients, and then if necessary and / or desired, molding and / or packaging the product into a desired single dose or multiple dose unit.

[0057] The "drug" of the present invention can be prepared according to known methods, such as the methods described in the general rules for preparation of the Chinese Pharmacopoeia (2020 edition), the Japanese Pharmacopoeia (Japanese Pharmacopoeia) 16th edition, the United States Pharmacopoeia (United States Pharmacopoeia) and the European Pharmacopoeia (European Pharmacopoeia) 9th edition. The specific preparation method depends on the dosage form.

[0058] The first active ingredient and pharmaceutically acceptable excipients in the "medicament" of the present invention will vary according to the attributes, body shape and / or condition of the subject to be treated and further according to the administration route of the composition. The medicament may contain between 0.1% and 100% (w / w) of the first active ingredient.

[0059] "Treatment" as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progression of, or preventing the condition or disorder or one or more symptoms of such condition or disorder to which the term applies, unless otherwise indicated. The term "treat" as used herein refers to the act of treating, as "treat" is defined immediately above.

[0060] The "effective amount" described in the present invention refers to an amount sufficient to induce a desired biological response. The effective amount of the active ingredients of the present invention may vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject. In certain embodiments, the effective amount is a therapeutically effective amount. The effective amount is the amount of the first active ingredient described in the present invention in a single dose. In certain embodiments, the effective amount is the combined amount of the active ingredients described in the present invention in multiple doses.

[0061] The "therapeutically effective amount" described in the present invention is an amount sufficient to provide a therapeutic benefit in the treatment of a disease or sufficient to delay or minimize one or more symptoms associated with the disease. The therapeutically effective amount of a Chinese medicine composition or Chinese medicine extract means the amount of a therapeutic agent that provides a therapeutic benefit in the treatment of a disease alone or in combination with other therapies. The term "therapeutically effective amount" may encompass an amount that improves overall therapy, reduces or avoids symptoms, signs or causes of a disease and / or enhances the therapeutic efficacy of another therapeutic agent. In certain embodiments, a therapeutically effective amount is an amount sufficient to treat any disease or disease described.

[0062] The terms "subject" or "patient" as used in the present invention are well known in the art and are used interchangeably herein to refer to mammals, including dogs, cats, rats, mice, monkeys, cows, horses, goats, sheep, pigs, camels, and most preferably humans. The term does not represent a particular age or sex. Thus, adult and newborn subjects, whether male or female, are encompassed.

[0063] The Chinese medicine composition or pharmaceutical composition described in the present invention can also be used as one of the raw materials contained in medicines, functional foods or health products.

[0064] Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention. The experimental methods described in the following embodiments are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.

[0065] The cat's claw, dandelion, cyperus rotundus and radix spatholobi in the present invention are conventional Chinese medicinal pieces purchased from the Chinese medicinal piece factory of Guangdong Provincial Medicinal Materials Company.

[0066] Chinese medicine composition of Example 1-2 and Comparative Example 1-2

[0067] [Preparation method]

[0068] According to the formula of the Chinese medicine composition in Table 1, take the formulated amount of cat's claw, dandelion, cyperus and thyme, mix them, add 10 times the amount of water, reflux and extract twice, each time for 1.5 hours, combine the filtrate, and concentrate to a relative density of 1.512g / ml (50℃).

[0069] Table 1 Formula of the Chinese medicine composition of the embodiment and comparative example (unit: weight portion)

[0070] Cat's Claw Dandelion Cyperus rotundus Tiankuizi Example 1 5 3 2 2 Example 2 5 1 8 6 Comparative Example 1 1 1 1 1 Comparative Example 2 5 3 2* 2

[0071] *Indicates that Herba Prunellae is used instead of Cyperus rotundus.

[0072] [Efficacy verification]

[0073] The present invention uses propylthiouracil (PTU) to induce a hypothyroidism and thyroid nodule model to explore the therapeutic and protective effects of a traditional Chinese medicine composition on the thyroid gland.

[0074] 1. Experimental Materials

[0075] 1.1 Drugs and reagents

[0076] Levothyroxine sodium tablets (Euthyroxine 50 μg / tablet) were purchased from Merck Pharmaceutical (Darmstadt, Germany); PTU (propylthiouracil) was purchased from Beijing Solarbio Technology Co., Ltd.; aspartate aminotransferase (AST / GOT) test kit, alanine aminotransferase (ALT / GPT) test kit, and urea nitrogen (BUN) test kit were all purchased from Nanjing Jiancheng Bioengineering Institute.

[0077] 1.2 Experimental animals

[0078] 70 male SD rats (180-200 g) were purchased from Guangdong Experimental Animal Center. All experimental animals were kept in an SPF barrier animal room with a fixed temperature (22±2°C), stable humidity (50±10%) and a 12-hour light / dark cycle.

[0079] 2. Animal grouping and drug administration

[0080] After 3 days of adaptive feeding, the rats were randomly divided into 6 groups, namely, blank control group (CON), model group (MOD), positive drug group (Euthyrox), Chinese medicine example 1 group (ZY1), Chinese medicine example 2 group (ZY2), Chinese medicine comparative example 1 group (DB1), and Chinese medicine comparative example 2 group (DB1); there were 9 rats in the blank control group, 11 rats in the model group, and 10 rats in each of the other groups.

[0081] The blank control group did not receive any treatment and was injected with normal saline of the corresponding volume of drug dose according to body weight every day. The remaining rats in each group were subcutaneously injected with 1mg / 100g / d PTU solution according to body weight every day for 28 days to induce thyroid nodules and develop thyroid nodule models. In addition, the positive drug group was given Euthyrox 2μg / 100g / d by gavage for 28 days. The Chinese medicine group was given a Chinese medicine combination liquid of 0.378g / 100g / d and gavage for 28 days.

[0082] 3. Blood and tissue collection

[0083] After 4 weeks of drug intervention, all rats were anesthetized by isoflurane. Blood was collected from the abdominal aorta, placed at 4°C for 1 hour, and centrifuged at 3500r / min for 15 minutes. The supernatant was collected and stored at -80°C for subsequent use. After blood collection, the neck skin was cut to expose the thyroid tissue and lymphatic tissue, which were completely removed and weighed to calculate the relative thyroid mass [thyroid mass (mg) / rat body weight (g)]. The liver, kidney, lung, spleen, intestine and their contents were quickly removed. Part of the thyroid, liver and kidney tissues were fixed in 4% paraformaldehyde for immunohistochemical staining, while the other part was frozen in liquid nitrogen and stored at -80°C; the lungs, spleen, intestine and their contents were quenched with liquid nitrogen and stored in a -80°C refrigerator.

[0084] 4. Histopathological examination

[0085] The embedded thyroid tissue was cut into 1 mm pieces, fixed in 2 pieces, and then dehydrated, infiltrated, and embedded. After being prepared into paraffin blocks, they were cut into 4 μm thick sections and dewaxed. Then they were stained with hematoxylin-eosin and dehydrated with ethanol and xylene in grades to make the sections transparent. Then they were sealed with neutral glue and the pathological changes of the thyroid (thyroid follicle morphology, glial cell distribution, fibroblast and epithelial cell morphology were used to evaluate thyroid nodules) were observed under a light microscope.

[0086] 5. Biochemical analysis

[0087] Enzyme-linked immunosorbent assay (ELISA) was used to detect serum T3, T4, and TSH hormone levels to evaluate the anti-hypothyroidism effect of the Chinese medicine compound. Serum interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) were also detected to evaluate the anti-inflammatory efficacy of the Chinese medicine compound. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and blood urea nitrogen (BUN) levels were also detected to evaluate liver and kidney function.

[0088] 6. Experimental results

[0089] 6.1 Construction of rat thyroid nodule model using PTU

[0090] After 4 weeks of PTU gavage, the thyroid gland in the model group became significantly red and swollen, and the volume increased compared with the blank control group, indicating that the thyroid nodule model was successfully established. Figure 1 shown.

[0091] 6.2 General Observations

[0092] PTU is an antithyroid drug that inhibits the synthesis of THs by inhibiting the iodination catalyzed by thyroid peroxidase and the coupling of tyrosine residues on thyroglobulin, thereby inducing the formation of thyroid nodule models. The effects of traditional Chinese medicine compositions on the thyroid gland of rats can be systematically evaluated by observing the general signs and changes in body weight of rats.

[0093] The results are shown in Table 2.

[0094] Four weeks after modeling, the rats in the model group showed symptoms such as rough hair, slow movements, pale skin, indifference, and drowsiness, indicating that the rats were in a low metabolic state caused by PTU. The body weight of the rats in the model group was lower than that in the blank control group (P < 0.05), indicating that PTU induced hypothyroidism in rats, reduced the metabolic level in the body, and reduced appetite in rats.

[0095] After treatment, compared with the model group, the symptoms of all treatment groups were improved except for Chinese medicine comparative example groups 1 and 2. Compared with the model group, the physique of rats in the positive drug group was significantly increased (P < 0.05), while the body weight of other treatment groups did not change significantly (P > 0.05), but compared with Chinese medicine comparative example groups 1 and 2, the physique of SD rats in Chinese medicine example groups 1 and 2 showed an increasing trend, as shown in Table 2.

[0096] Table 2 Effect of Chinese medicine composition on rat body weight

[0097]

[0098] Note: Different letters in the table indicate significant differences among the groups (P < 0.05).

[0099] 6.3 Reduce thyroid volume

[0100] Figure 2 is the size of the thyroid gland after treatment. Compared with the blank control group, the thyroid gland volume of the rats in the model group was significantly increased (P<0.05), and the average body weight of the rats in the model group was 100g lighter than that in the blank control group, indicating that the drug PTU successfully caused the thyroid gland tissue of the rats to swell.

[0101] After four weeks of treatment, compared with the model group, the thyroid volume of the positive drug group, Chinese medicine example group 1 and group 2 was reduced, among which the treatment effect of Chinese medicine example group 1 was the best, similar to the positive drug group, and the enlargement of thyroid tissue was significantly improved (P<0.05).

[0102] 6.4 Improvement of thyroid function in rats

[0103] After treatment with the Chinese herbal composition, the serum THs level of rats in each group was detected to verify whether the Chinese herbal composition could regulate thyroid function.

[0104] The results are shown in Table 3.

[0105] Table 3 Effect of Chinese medicine composition on rat serum THs

[0106]

[0107] Note: Different letters in the table indicate significant differences among the groups (P < 0.05).

[0108] The results showed that the thyroid function of rats in the PTU drug-induced model group was abnormal, resulting in an increase in TSH, T3, and T4 compared with the blank control group (P<0.05). The above-mentioned dysfunctions in the positive drug group, the Chinese medicine example 1 group, and the 2 groups were all improved (P<0.05), indicating that the Chinese medicine compositions provided in Examples 1 and 2 of the present invention have a good regulatory ability on THs.

[0109] At the same time, compared with the model group, there was no significant difference in the TSH content in the serum of the rats in the Chinese medicine comparison example group 1 and group 2 (P>0.05), and the contents of T3 and T4 in the serum were significantly reduced (P>0.05), but compared with the Chinese medicine example group 1 and group 2, the THs level in the serum of the rats had a significant difference (P<0.05), indicating that the Chinese medicine compositions provided in Examples 1 and 2 of the present invention have a better effect on improving the thyroid function of rats than the Chinese medicine compositions provided in Comparative Examples 1 and 2.

[0110] 6.5 Improvement of inflammation caused by thyroid nodules in rats

[0111] After treatment with the Chinese medicine composition, the expression levels of inflammatory factors IL-6 and TNF-α in the serum of each group of rats were detected to verify whether the Chinese medicine composition has the effects of anti-inflammatory, detumescence and dispersing nodules.

[0112] The results are shown in Table 4.

[0113] Table 4 Effects of Chinese medicine combination on inflammatory factors in rats

[0114]

[0115] Note: Different letters in the table indicate significant differences among the groups (P < 0.05).

[0116] The results showed that the expression level of inflammatory factors in the serum of rats in the model group was significantly higher than that in the blank control group (P<0.05).

[0117] Compared with the model group, the expression level of inflammatory factors in each administration group was effectively reduced (P<0.05). At the same time, compared with the Chinese medicine comparative example group 1 and group 2, the expression level of inflammatory factors in the serum of rats in the Chinese medicine example group 1 and group 2 was significantly reduced, indicating that compared with the Chinese medicine compositions provided in comparative examples 1 and 2, the Chinese medicine compositions provided in Examples 1 and 2 of the present invention showed better regulatory ability on IL-6 and TNF-α, and played a better anti-inflammatory effect.

[0118] 6.6 Effects on liver and kidney coefficients

[0119] This prescription contains 4 Chinese medicines. According to the guidance of TCM medication theory, their combination may cause potential side effects or adverse reactions. Therefore, the inventors also pay attention to the changes in serum liver and kidney injury markers to ensure the safety of the drug.

[0120] Depend on Figure 3 It can be seen that compared with the blank control group, there were no statistically significant differences in the levels of ALT, AST and BUN in the serum of rats among the groups (P>0.05), indicating that the Chinese medicine composition provided by the present invention will not produce toxic side effects on the liver and kidneys, is in line with the standards for safe medication, and can be used in subsequent human experiments.

[0121] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A Chinese medicine composition, characterized in that: The invention is composed of the following raw materials in parts by weight: 1-120 parts of cat's claw, 1-30 parts of dandelion, 1-20 parts of cyperus rotundus and 1-20 parts of thyme seeds.

2. The Chinese medicine composition according to claim 1, characterized in that: The mass ratio of cat's claw, dandelion, cyperus rotundus and thyme seeds is 5-6:1-4:2-8:2-6.

3. The method for preparing the Chinese medicine composition according to claim 1 or 2, characterized in that: The method comprises the following steps: mixing and crushing a formula amount of cat's claw, dandelion, cyperus rotundus and thyme seeds; or Extracting the formulated amounts of cat's claw, dandelion, cyperus rotundus and thyme seeds, purifying and enriching them, thus obtaining the traditional Chinese medicine composition.

4. Use of the Chinese medicine composition according to claim 1 in the preparation of a drug for increasing thyroid hormone to treat diseases.

5. Use of the Chinese medicine composition according to claim 1 in the preparation of a drug for treating diseases by reducing THs levels.

6. Use of the Chinese medicine composition according to claim 1 in preparing a medicine for treating hypothyroidism or thyroid nodules.

7. The use according to claim 4 or 5, characterized in that: The diseases include hypothyroidism and / or thyroid nodules.

8. The use according to claim 7, characterized in that: The thyroid nodule includes at least one of nodular goiter, thyroid adenoma, acute thyroiditis, chronic thyroid adenitis and thyroid micropapillary carcinoma.

9. A pharmaceutical composition for treating thyroid disease, characterized in that: The invention comprises the Chinese medicine composition according to claim 1 or 2 and medically acceptable excipients.

10. The pharmaceutical composition according to claim 9, characterized in that The dosage form of the pharmaceutical composition is tablets, pills, dripping pills, capsules, granules, powders, suppositories, powders, ointments, patches, injections, oral solutions, suspensions, sprays, lotions, drops, liniments or emulsions.

Citation Information

Patent Citations

  • Traditional Chinese medicine composition for treating thyroid cyst and preparation method thereof

    CN116407594A

  • Traditional Chinese medicine composition for treating thyroiditis

    CN117482196A